In a placebo controlled double blinded study, the clinical, cardiological and hemorheological effects of Propentofyllin (Karsivan®), a xanthin derivate were evaluated in 33 dogs with a defined cardiac disease (mitral valve endocardosis) according to NHYA (grade 1).
The evaluated group was heterogeneous concerning breed, sex and age and the patients used in this study have not received any other cardiac therapy before and during the period of investigation (12 weeks).
The dogs were randomised into two groups receiving either placebo therapy or Propentofyllin (Karsivan®).
History and clinical findings, as well as echocardiographical and hemorheological data, were documented and controlled prior to and at 4, 8 and 12 weeks of treatment.
12 parameters - heart frequency, blood pressure, fractional shortening, endsystolic volume index, dimension of the left atrium, blood viscosity (adjusted at 40% Hct.), plasma viscosity, erythrocyte aggregation and flexibility, and fibrinogen - were evaluated and statistically analysed.
A statistically significant change in the echocardiographic and hemorheological parameters during administration of Propentofyllin (Karsivan®) could not be established.